Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.81 |
| ▸ | MEN1 | O00255 | 4/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.81 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.75 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.75 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | TNKS | O95271 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | BCHE | P06276 | 1/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370223 | 1.00 | HPGD (0.81) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL4650047 | 0.89 | HPGD (1.00) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL21704890 | 0.88 | AKR1C3 (0.71) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL312255 | 0.86 | AKR1C3 (1.00) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL22806648 | 0.85 | HPGD (0.72) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL30933461 | 0.84 | HPGD (0.75) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL9080220 | 0.83 | AKR1C3 (0.72) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL6244185 | 0.83 | HPGD (0.62) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL311588 | 0.82 | HPGD (0.76) | HPGDCYP3A4KDM4EMEN1KMT2A | |
| SCHEMBL311714 | 0.82 | HPGD (0.76) | HPGDCYP3A4KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282871-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TIANJIN LIPOGEN TECH CO LTD (CN) | 2025-09-11 | — | — | US | claimed |
| US-20240285755-A1 | Adjuvants | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-08-29 | — | — | US | claimed |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-22 | — | — | US | claimed |
| EP-4346894-A1 | ADJUVANTS | GlaxoSmithKline Biologicals S.A. (BE) | 2024-04-10 | — | — | EP | claimed |
| EP-4342492-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | Tianjin Lipogen Technology Co., Ltd (CN) | 2024-03-27 | — | — | EP | claimed |
| CN-117396222-A | Pharmaceutical combination and use thereof | 天津立博美华基因科技有限责任公司 | 2024-01-12 | — | — | CN | claimed |
| EP-4228657-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2023-08-23 | — | — | EP | claimed |
| CN-116390764-A | Crystalline polymorphic forms of STING agonist bound to metal ions capable of modulating immune responses | 密歇根大学董事会 | 2023-07-04 | — | — | CN | claimed |
| WO-2022248353-A1 | ADJUVANTS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-12-01 | — | — | WO | claimed |
| WO-2022081993-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-21 | — | — | WO | claimed |
| US-20220031825-A1 | IMMUNOLOGICAL ADJUVANT AND VACCINE COMPOSITION INCLUDING STING AGONIST | QURATIS INC (KR) | 2022-02-03 | — | — | US | claimed |
| WO-2020227159-A2 | METHODS OF MODULATING IMMUNE ACTIVITY | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-11-12 | — | — | WO | claimed |
| US-20180311206-A1 | USE OF STING AGONISTS TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION | UNIV DREXEL (US) | 2018-11-01 | — | — | US | claimed |
| US-20170281589-A1 | USE OF STING AGONISTS TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION | UNIV DREXEL (US) | 2017-10-05 | — | — | US | claimed |
| US-9642830-B2 | Use of sting agonists to treat hepatitis B virus infection | DREXEL UNIVERSITY (US) | 2017-05-09 | — | — | US | claimed |
| US-20160256434-A1 | USE OF STING AGONISTS TO TREAT HEPATITIS B VIRUS INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-08 | — | — | US | claimed |
| EP-3060056-A2 | USE OF STING AGONISTS TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION | Drexel University (US) | 2016-08-31 | — | — | EP | claimed |
| WO-2015061294-A2 | USE OF STING AGONISTS TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION | PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A/ (US) | 2015-04-30 | — | — | WO | claimed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2015061294-A2 | USE OF STING AGONISTS TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION | PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A/ (US) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285755-A1 | Adjuvants | STING1, TLR3, TLR9 | HPGD 3394/4885CYP3A4 4646/4885KDM4E 3012/4885 |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | STING1, CGAS, IRF3 | HPGD 2823/4885CYP3A4 2396/4885KDM4E 4411/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | HPGD 2062/4885CYP3A4 4830/4885KDM4E 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.